The Conversation (0)
March 16, 2022
The common shares of Nirvana Life Sciences Inc., have been approved for listing on the CSE.
Listing and disclosure documents will be available at www.thecse.com on the trading date.
Nirvana Life Sciences Inc. is focused on developing medical products and regimens that address addiction. Nirvana is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency and other health problems.
The Exchange is accepting Market Maker applications for NIRV. Please email: Trading@theCSE.com
If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com
Source
NIRV:CC
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.
07 April 2022
Nirvana Life Sciences
Psychedelics for Opioid Addiction Recovery and Pain Management
Psychedelics for Opioid Addiction Recovery and Pain Management Keep Reading...
30 October
Appendix 4C Cashflow Statementand Quarterly Activities Report
The Calmer Co. International Limited (ASX: CCO) submits the following Activities Report and Appendix 4C Cash Flow Statement for the three-month period ended 30th September 2026. Highlights Record quarterly revenue of $2.44 million, up 42% on the prior quarter, driven by wholesale and B2B sales... Keep Reading...
07 October
Coles Orders Fiji Kava® FZZR™ – First Flavoured Kava Product to Launch in Australia
The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products that promote relaxation and sleep support, refers to its ASX announcement of 24 June 2026 and is pleased to advise that Coles has placed its initial order... Keep Reading...
28 August
Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update
Q4 Fiscal 2025 Highlights Revenue of $2.3 million, a 29.0% increase over Q3 2025 Gross profit of $1.4 million, compared to a gross profit of $0.8 million in Q3 2025 Cash position of $0.5 million as of August 31, 2025 Subsequent to Quarter End On April 18, 2026, President Donald Trump signed an... Keep Reading...
17 August
The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million
Brisbane, Australia - The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products that promote relaxation and sleep support, is pleased to announce the execution of an Exclusive Distribution Agreement with a... Keep Reading...
29 July
Psychedelics Market Trends: H1 2026 Review and Forecast
The psychedelic medicine market is moving swiftly from speculative research mode toward an institutional, prescription-oriented framework as federal policy in the US becomes more supportive.President Donald Trump’s April 18 executive order on ibogaine and other psychedelic therapies helped... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00